Jean-Baptiste Brière (J-B Briere, Jean Baptiste Briere, Jean-Baptiste Briere)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Venues

Expert review of pharmacoeconomics & outcomes research

Vascular medicine (London, England)

Journal of market access & health policy

PloS one

Bayer Pharma AG

Aix-Marseille Université (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Bayer Pharma AG Aug 01 2010

Germany

Health Economist :: Health Economics and outcome research

Education History

Aix-Marseille Université Dec 01 2017

France

PHD :: Publique health

EU2P Sep 01 2016 - Sep 01 2018

Germany

MSC :: Pharmacology and pharmaco-epidemiology

Université Paris Dauphine Jul 01 2007 - Jul 01 2008

France

MSC :: Health economics and management of health care systems

Universite Angers Jul 01 2000 - Jul 01 2008

France

PHD :: Pharmacy

Publications

Pierre Levy, Tobiasz Lemański, Catriona Crossan, Anna Lefebvre, Jean-Baptiste Brière, Luca Degli Esposti, Zeba M Khan
Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective. Expert review of pharmacoeconomics & outcomes research (2024)
Pierre Levy, Tobiasz Lemański, Anna Lefevbre, Catriona Crossan, Jean-Baptiste Brière, Luca Degli Esposti, Zeba M Khan
Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective. Expert review of pharmacoeconomics & outcomes research (2024)
Pierre Levy, Tobiasz Lemański, Catriona Crossan, Anna Lefebvre, Jean-Baptiste Brière, Luca Degli Esposti, Zeba M Khan
Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective. Expert review of pharmacoeconomics & outcomes research (2024)
Zeba M Khan, Jean-Baptiste Brière, Elzbieta Olewinska, Fatma Khrouf, Mateusz Nikodem
Ivabradine in patients with heart failure: a systematic literature review. Journal of market access & health policy 11 (1) (2023)
Laura Portas, Rupert Bauersachs, Kevin Bowrin, Jean-Baptiste Brière, Alexander Cohen, Maria Huelsebeck, Schuyler Jones, Jennifer K Quint
Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England. Vascular medicine (London, England) 27 (5) (2022)
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Brière
Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain. PloS one 17 (4) (2022)
J A Spoorendonk, Jean-Baptiste Brière, Kevin Bowrin, A Millier, M Coppens, S Tempelaar, B Verheggen
Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands. Journal of medical economics 24 (1) (2021)
Erkki Soini, Outi Virtanen, Saku Väätäinen, Jean-Baptiste Brière, Kevin Bowrin, Aurelie Millier
Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Advances in therapy 37 (7) (2020)

Jean-Baptiste Brière.css-eqlu8i{font-size:small;padding-left:4px;} (J-B Briere, Jean Baptiste Briere, Jean-Baptiste Briere)

Publication Activity (10 Years)

Top Topics

Top Venues

Jean-Baptiste Brière (J-B Briere, Jean Baptiste Briere, Jean-Baptiste Briere)